|
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer J Clin 2018; 68(6):394-424. 2. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global cancer observatory: cancer today. Lyon, France: international agency for research on cancer. 2018; 3(20): 2019. 3. Panigrahi GK, Praharaj PP, Kittaka H, Mridha AR, Black OM, Singh R, et al. Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients. Cancer Med 2019; 8(3):1110-23. 4. Pakzad R, Rafiemanesh H, Ghoncheh M, Sarmad A, Salehiniya H, Hosseini S, et al. Prostate cancer in Iran: trends in incidence and morphological and epidemiological characteristics. Asian Pacific J Cancer Prevention 2016; 17(2): 839-43. 5. Tonon L, Fromont G, Boyault S, Thomas E, Ferrari A, Sertier AS, et al. Mutational profile of aggressive, localised prostate cancer from African Caribbean men versus European ancestry men. Eur Urol 2019; 75(1):11-5. 6. Pienta KJ, Esper PS. Risk factors for prostate cancer. Annals Internal Med 1993; 118(10): 793-803. 7. Chan JM, Holick CN, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, et al. Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States). Cancer Causes Control 2006; 17(2): 199-208. 8. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. New England J Med 2000; 343(2):78-85. 9. Hjelmborg JB, Scheike T, Holst K, Skytthe A, Penney KL, Graff RE, et al. The Heritability of Prostate Cancer in the Nordic Twin Study of CancerThe Heritability of Prostate Cancer. Cancer Epidemiol Biomarkers Prevention 2014; 23(11): 2303-10. 10. Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, et al. Familial risk and heritability of cancer among twins in Nordic countries. Jama 2016; 315(1):68-76. 11. Alvarez-Cubero MJ, Saiz M, Martinez-Gonzalez LJ, Alvarez JC, Lorente JA, Cozar JM. Genetic analysis of the principal genes related to prostate cancer: a review. Urol Oncol 2013; 31(8): 1419-29. 12. Benafif S, Kote-Jarai Z, Eeles RA. A review of prostate cancer genome-wide association studies (GWAS). Cancer Epidemiol Biomarkers Prev 2018; 27(8): 845-57. 13. McLean MH, El-Omar EM. Genetics of gastric cancer. Nature Reviews Gastroenterol Hepatol 2014; 11(11): 664-74. 14. Hua JT, Ahmed M, Guo H, Zhang Y, Chen S, Soares F, et al. Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19. Cell. 2018; 174(3):564-75. 15. Hedelin M, Bälter KA, Chang ET, Bellocco R, Klint Å, Johansson JE, et al. Dietary intake of phytoestrogens, estrogen receptor‐beta polymorphisms and the risk of prostate cancer. Prostate 2006; 66(14):1512-20. 16. Lattrich C, Häring J, Schüler S, Skrzypczak M, Ortmann O, Treeck O. Polymorphisms in the promoter region of estrogen receptor β gene in endometrial cancer. Arch Gynecol Obstetrics 2014; 289(3): 631-5. 17. Bishr M, Saad F. Overview of the latest treatments for castration-resistant prostate cancer. Nature Reviews Urol 2013; 10(9): 522-8. 18. Mills IG. Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nature Reviews Cancer 2014; 14(3):187-98. 19. Gao P, Xia JH, Sipeky C, Dong XM, Zhang Q, Yang Y, et al. Biology and clinical implications of the 19q13 aggressive prostate cancer susceptibility locus. Cell. 2018; 174(3): 576-89. 20. Shui IM, Lindström S, Kibel AS, Berndt SI, Campa D, Gerke T, Penney KL, Albanes D, Berg C, Bueno-de-Mesquita HB, Chanock S. Prostate cancer (PCa) risk variants and risk of fatal PCa in the national cancer institute breast and prostate cancer cohort consortium. Eur Urol 2014; 65(6):1069-75. 21. Amin Al Olama A, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, Benlloch S, et al. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Human Molecular Genetics 2013; 22(2):408-15. 22. Blumenthal RD, Leon E, Hansen HJ, Goldenberg DM. Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer 2007; 7(1):1-5. 23. Alkelai A, Lupoli S, Greenbaum L, Kohn Y, Kanyas-Sarner K, Ben-Asher E, et al. DOCK4 and CEACAM21 as novel schizophrenia candidate genes in the Jewish population. Int J Neuropsychopharmacol 2012; 15(4): 459-69. 24. Gao P, Wei GH. Genomic insight into the role of lncRNAs in cancer susceptibility. Int J Molecular Sci 2017; 18(6):1239. 25. Guo H, Ahmed M, Zhang F, Yao CQ, Li S, Liang Y, et al. Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nature Genetics 2016; 48(10): 1142-50. 26. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer J Clin 2011; 61(2): 69-90. 27. Noble RL. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 1977; 37(6): 1929-33. 28. Ricke WA, Wang Y, Cunha GR. Steroid hormones and carcinogenesis of the prostate: the role of estrogens. Differentiation. 2007; 75(9): 871–82 29. Kuiper GG, Enmark E, Pelto-Huikko M. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 1996; 93: 5925–30. 30. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996; 392: 49–53. 31. Kuiper GG, Carlsson BO, Grandien KA, Enmark E, Häggblad J, Nilsson S, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology. 1997; 138(3): 863-70. 32. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, et al. Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 2001; 159(1): 79-92. 33. Prins GS, Marmer M, Woodham C, Chang W, Kuiper G, et al. Estrogen receptor-beta messenger ribonucleic acid ontogeny in the prostate of normal and neonatally estrogenized rats. Endocrinology 1998; 139: 874–83. 34. Yager JD. Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr. 2000; 27: 67–73. 35. Risbridger G, Wang H, Young P, Kurita T, Wong YZ, Lubahn D, Gustafsson JA, Cunha G. Evidence that epithelial and mesenchymal estrogen receptor-α mediates effects of estrogen on prostatic epithelium. Developmental Biol 2001; 229(2): 432-42. 36. Fujimura T, Takahashi S, Urano T, Kumagai J, Ogushi T, Horie‐Inoue K, et al. Increased expression of estrogen‐related receptor α (ERRα) is a negative prognostic predictor in human prostate cancer. Int J Cancer 2007; 120(11): 2325-30. 37. Koehler KF, Helguero LA, Haldosén LA, Warner M, Gustafsson JA. Reflections on the discovery and significance of estrogen receptor β. Endocrine reviews. 2005; 26(3):465-78. 38. Tanaka Y, Sasaki M, Kaneuchi M, Shiina H, Igawa M, Dahiya R. Polymorphisms of estrogen receptor alpha in prostate cancer. Molecular Carcinogenesis: Published in cooperation with the University of Texas MD Anderson Cancer Center. 2003; 37(4): 202-8. 39. Suzuki K, Nakazato H, Matsui H, Koike H, Okugi H, Kashiwagi B, et al. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol‐O‐methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer: Interdisciplinary Int J Am Cancer Society 2003; 98(7): 1411-6. 40. Low YL, Taylor JI, Grace PB, Mulligan AA, Welch AA, Scollen S, et al. Phytoestrogen exposure, polymorphisms in COMT, CYP19, ESR1, and SHBG genes, and their associations with prostate cancer risk. Nutr Cancer 2006; 56(1): 31-9. 41. Sobti RC, Gupta L, Singh SK, Seth A, Kaur P, Thakur H. Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population. Cancer Genetics Cytogenetics 2008; 185(2): 78-85. 42. Pettersson K, Grandien K, Kuiper GG, Gustafsson JA. Mouse estrogen receptor β forms estrogen response element-binding heterodimers with estrogen receptor α. Molecular Endocrinol 1997; 11(10): 1486-96. 43. Kuiper GG, Gustafsson JÅ. The novel estrogen receptor-β subtype: potential role in the cell-and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett 1997; 410(1): 87-90. 44. Chae YK, Huang HY, Strickland P, Hoffman SC, Helzlsouer K. Genetic polymorphisms of estrogen receptors α and β and the risk of developing prostate cancer. PloS One 2009; 4(8):e6523.
|
.png)
.png){kind=logo}
